Company / Accounts Receivable
BioCardia, Inc. Accounts Receivable History
FY2011-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$95.0K
FY2017
5-year range
$67.0K / $95.0K
FY2013-FY2017
Trend
+28.4%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $67,000 to $95,000 over the past 6 years.
Based on SEC 10-K filings.
$95,000 in FY2017.
Improved from $67,000 to $95,000 over the past 6 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2017, accounts receivable increased 28.4% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2017 | $95.0K | +28.4% |
| FY2016 | $74.0K | +10.4% |
| FY2011 | $67.0K | - |
As of FY2017 · SEC Form 10-K · Last checked Jun 21, 2026